CY2016027I2 - Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων - Google Patents

Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων

Info

Publication number
CY2016027I2
CY2016027I2 CY2016027C CY2016027C CY2016027I2 CY 2016027 I2 CY2016027 I2 CY 2016027I2 CY 2016027 C CY2016027 C CY 2016027C CY 2016027 C CY2016027 C CY 2016027C CY 2016027 I2 CY2016027 I2 CY 2016027I2
Authority
CY
Cyprus
Prior art keywords
polymer compounds
polyalkylene polymer
polyalkylene
compounds
polymer
Prior art date
Application number
CY2016027C
Other languages
Greek (el)
English (en)
Other versions
CY2016027I1 (el
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY2016027I1 publication Critical patent/CY2016027I1/el
Publication of CY2016027I2 publication Critical patent/CY2016027I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
CY2016027C 2002-01-18 2016-08-05 Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων CY2016027I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18
PCT/US2003/001559 WO2003061577A2 (en) 2002-01-18 2003-01-17 Polyalkylene glycol with moiety for conjugating biologically active compound

Publications (2)

Publication Number Publication Date
CY2016027I1 CY2016027I1 (el) 2017-06-28
CY2016027I2 true CY2016027I2 (el) 2017-06-28

Family

ID=27613339

Family Applications (2)

Application Number Title Priority Date Filing Date
CY2016027C CY2016027I2 (el) 2002-01-18 2016-08-05 Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων
CY20201100115T CY1122841T1 (el) 2002-01-18 2020-02-06 Πολυαλκυλενικες πολυμερικες ενωσεις και χρησεις αυτων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20201100115T CY1122841T1 (el) 2002-01-18 2020-02-06 Πολυαλκυλενικες πολυμερικες ενωσεις και χρησεις αυτων

Country Status (35)

Country Link
US (2) US8017733B2 (enExample)
EP (3) EP1476181B1 (enExample)
JP (5) JP2005526151A (enExample)
KR (1) KR100964411B1 (enExample)
CN (2) CN101700401B (enExample)
AU (1) AU2003210564B2 (enExample)
BE (1) BE2016C040I2 (enExample)
BG (1) BG66525B1 (enExample)
BR (1) BRPI0306993B8 (enExample)
CA (4) CA2753899C (enExample)
CY (2) CY2016027I2 (enExample)
CZ (1) CZ2004877A3 (enExample)
DK (2) DK1476181T3 (enExample)
EA (2) EA011829B1 (enExample)
EE (1) EE05509B1 (enExample)
ES (2) ES2774801T3 (enExample)
FR (1) FR16C0034I2 (enExample)
GE (2) GEP20064024B (enExample)
HU (4) HUE047557T2 (enExample)
IL (1) IL163006A (enExample)
IS (1) IS2989B (enExample)
LU (1) LU93162I2 (enExample)
ME (2) ME00239B (enExample)
MX (1) MXPA04006855A (enExample)
NL (1) NL300826I2 (enExample)
NO (3) NO339857B1 (enExample)
NZ (1) NZ534708A (enExample)
PL (2) PL213322B1 (enExample)
PT (1) PT3025726T (enExample)
RS (1) RS55578B1 (enExample)
SI (2) SI1476181T1 (enExample)
SK (1) SK3102004A3 (enExample)
UA (1) UA82184C2 (enExample)
WO (1) WO2003061577A2 (enExample)
ZA (1) ZA200406555B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
AP2005003249A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals.
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US9125880B2 (en) * 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
KR101162908B1 (ko) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1635875B8 (en) 2003-06-26 2008-12-24 pSivida Inc In-situ gelling drug delivery system
WO2005000268A2 (en) 2003-06-26 2005-01-06 Control Delivery Systems, Inc. Bioerodible sustained release drug delivery systems
WO2005118537A2 (en) * 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Arylpiperazine derivatives as adrenergic receptor antagonists
EP1827501B2 (en) 2004-12-21 2013-11-20 Nektar Therapeutics Stabilized polymeric thiol reagents
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
CN101505800A (zh) 2005-07-08 2009-08-12 艾伦药物公司 经由Mitsunobu反应制备VLA-4拮抗剂的聚乙二醇化共轭物
TW200817369A (en) * 2006-05-22 2008-04-16 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
WO2008066816A2 (en) * 2006-11-28 2008-06-05 The Board Of Trustees Of The University Of Illinois Derivatization or ligaton of peptides
TW200922624A (en) * 2007-07-11 2009-06-01 Enzon Pharmaceuticals Inc Polymeric drug delivery system containing a multi-substituted aromatic moiety
JP2010533233A (ja) * 2007-07-11 2010-10-21 エンゾン ファーマシューティカルズ，インコーポレーテッド 芳香族アリル酸を含むポリマー性薬剤送達システム
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
RU2496514C2 (ru) * 2008-06-05 2013-10-27 Займоджинетикс, Инк. Применение пэгилированных интерферонов типа iii для лечения гепатита с
EP2313457B1 (en) * 2008-07-31 2020-01-15 PharmaEssentia Corp. Peptide-polymer conjugates
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
WO2010140350A1 (ja) 2009-06-02 2010-12-09 パナソニック株式会社 ダウンミックス装置、符号化装置、及びこれらの方法
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
WO2016013911A1 (ko) * 2014-07-24 2016-01-28 에이비온 주식회사 페길화된 인터페론 -베타 변이체
EP3183264B1 (en) * 2014-08-19 2020-07-29 Biogen MA Inc. Pegylation method
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
SI3215193T1 (sl) 2014-11-06 2024-02-29 Pharmaessentia Corporation Dozirna shema za pegiliran interferon
EP3421442B1 (en) * 2017-06-28 2020-08-05 Construction Research & Technology GmbH Dispersant for inorganic particles
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
WO2020028715A1 (en) 2018-08-01 2020-02-06 Russell Alan J Amino-reactive positively charged atrp initiators that maintain their positive charge during synthesis of biomacro-initiators
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
WO1985003934A1 (fr) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Proteine modifiee chimiquement et son procede de preparation
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993012145A1 (en) 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
CA2176229C (en) 1993-11-10 2003-05-27 Carl W. Gilbert Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
FI972443A0 (fi) 1994-12-07 1997-06-09 Novo Nordisk As Polypeptidi, jonka allergeenisuus on vähentynyt
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
EP0856026A1 (en) * 1995-10-19 1998-08-05 Receptagen Corporation Discrete-length polyethylene glycols
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
AU726374B2 (en) 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
US5990237A (en) * 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
AU1825299A (en) * 1997-12-17 1999-07-05 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
ES2222689T3 (es) 1998-03-12 2005-02-01 Nektar Therapeutics Al, Corporation Derivados del polietilenglicol con grupos reactivos proximales.
WO1999055377A2 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
SG2008070138A (en) * 1998-10-16 2017-08-30 Biogen Ma Inc Polymer conjugates of interferon beta- 1a and their uses
EP1223986A2 (en) * 1999-06-11 2002-07-24 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
CA2380760A1 (en) 1999-08-27 2001-03-08 Maxygen Aps New interferon beta-like molecules
ATE317868T1 (de) * 1999-12-22 2006-03-15 Nektar Therapeutics Al Corp Sterisch gehinderte derivate von wasserlöslichen polymeren
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
EP1324779B1 (en) * 2000-09-29 2011-07-20 Schering Corporation Pegylated interleukin-10
TW593427B (en) 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
TR200301208T2 (tr) * 2001-02-01 2005-05-23 Biogen, Inc. Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.
PL367154A1 (en) 2001-02-27 2005-02-21 Maxygen Aps New interferon beta-like molecules
US7009033B2 (en) 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
EP1436012B1 (en) * 2001-10-18 2017-12-20 Nektar Therapeutics Polymer conjugates of opioid antagonists
HRP20040448A2 (en) * 2001-11-20 2006-02-28 Pharmacia Corporation Method for detecting cells with numerical chromosomal abnormalities
KR100488351B1 (ko) 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (en) * 2001-12-11 2006-05-17 Sun Bio Inc NOVEL MONOFUNCTIONAL POLYETHYLENE GLYCOL ALDEHYDES
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
AP2005003249A0 (en) 2002-09-09 2005-03-31 Nektar Therapeutics Al Corp Water-soluble polymer alkanals.
US9125880B2 (en) 2002-12-26 2015-09-08 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Also Published As

Publication number Publication date
EP1476181A2 (en) 2004-11-17
EP1476181B1 (en) 2016-03-23
NL300826I2 (enExample) 2017-03-16
NO339857B1 (no) 2017-02-06
EE05509B1 (et) 2012-02-15
CY2016027I1 (el) 2017-06-28
CN101700401B (zh) 2013-08-14
UA82184C2 (uk) 2008-03-25
GEP20074024B (en) 2007-01-10
HUE047557T2 (hu) 2020-04-28
BE2016C040I2 (enExample) 2022-05-17
NO344612B1 (no) 2020-02-10
ME00239B (me) 2011-05-10
KR100964411B1 (ko) 2010-06-15
SI3025726T1 (sl) 2020-03-31
JP5275125B2 (ja) 2013-08-28
NO2017013I1 (no) 2017-04-10
EA009783B1 (ru) 2008-04-28
CA2473526A1 (en) 2003-07-31
EA011829B1 (ru) 2009-06-30
JP2005526151A (ja) 2005-09-02
DK1476181T3 (en) 2016-05-23
IL163006A (en) 2011-01-31
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
WO2003061577A3 (en) 2003-10-02
EP3025726A1 (en) 2016-06-01
CY1122841T1 (el) 2021-10-29
US20120014916A1 (en) 2012-01-19
CA2473526C (en) 2013-10-22
MXPA04006855A (es) 2005-04-19
PL397261A1 (pl) 2012-03-26
EP3669887A1 (en) 2020-06-24
CZ2004877A3 (cs) 2004-12-15
NO20043422L (no) 2004-10-11
HK1224185A1 (en) 2017-08-18
JP6030717B2 (ja) 2016-11-24
BRPI0306993B8 (pt) 2021-05-25
KR20040081463A (ko) 2004-09-21
NZ534708A (en) 2007-05-31
RS63504A (sr) 2007-02-05
ES2566797T3 (es) 2016-04-15
ZA200406555B (en) 2005-11-30
EE200400105A (et) 2004-12-15
NO2017013I2 (no) 2018-08-20
CA2952488C (en) 2019-05-07
NO20151082A1 (no) 2015-08-26
HK1143553A1 (en) 2011-01-07
PL372728A1 (en) 2005-08-08
CA2753899A1 (en) 2003-07-31
BG108839A (bg) 2005-04-30
BG66525B1 (bg) 2016-04-28
JP2016014022A (ja) 2016-01-28
US8524660B2 (en) 2013-09-03
LU93162I2 (fr) 2016-10-03
HK1072721A1 (zh) 2005-09-09
FR16C0034I1 (enExample) 2016-09-23
WO2003061577A2 (en) 2003-07-31
IS2989B (is) 2017-11-15
PL213322B1 (pl) 2013-02-28
CA2753899C (en) 2014-03-25
CN1630530A (zh) 2005-06-22
HUS1600035I1 (hu) 2016-10-28
DK3025726T3 (da) 2019-12-09
CA2840490C (en) 2017-02-28
BR0306993A (pt) 2005-09-06
US20050107277A1 (en) 2005-05-19
CA2840490A1 (en) 2003-07-31
WO2003061577A8 (en) 2008-11-20
BRPI0306993B1 (pt) 2020-03-10
CN101700401A (zh) 2010-05-05
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
GEP20064024B (en) 2007-01-10
FR16C0034I2 (fr) 2019-10-04
CA2952488A1 (en) 2003-07-31
JP2013136756A (ja) 2013-07-11
EA200400962A1 (ru) 2005-06-30
EP3025726B1 (en) 2019-11-20
MEP35608A (hr) 2011-02-10
PT3025726T (pt) 2020-01-09
AU2003210564B2 (en) 2008-10-23
JP2009235409A (ja) 2009-10-15
EA200701386A1 (ru) 2007-10-26
HUP0500457A2 (hu) 2005-08-29
ES2774801T3 (es) 2020-07-22
EP1476181A4 (en) 2008-11-19
JP2012255156A (ja) 2012-12-27
HUP0500457A3 (en) 2012-09-28
US8017733B2 (en) 2011-09-13
HUE028163T2 (en) 2016-11-28
SK3102004A3 (sk) 2005-01-03

Similar Documents

Publication Publication Date Title
CY2016027I1 (el) Πολυμερικες ενωσεις πολυαλκυλενιου και χρησεις αυτων
CY2018009I1 (el) Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων
DE60316445D1 (de) Funktionalisiertes polymer und verbesserte vulkanisate daraus
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
CY2012025I1 (el) Υπο-ακετυλιωμενα και υπερ-ακετυλιωμενα μηνιγγοκοκκικα καψικα σακχαριδια
DE60225204D1 (de) Polymerelektrolyt und Hestellungsverfahren dafür
NL1025404A1 (nl) Pyrazolo-triazine verbindingen en gebruik daarvan.
DK1378554T3 (da) Hydrofile polymerkoncentrater
DE60226865D1 (de) Thermoplastische elastomerzusammensetzung
DE60228825D1 (de) Hochnukleierte thermoplastische gegenstände
DE60326611D1 (de) N und dergleichen
DE602004031607D1 (de) Propylenpolymerzusammensetzung und verwendung davon
DE60209252D1 (de) Stabilisierte polymerzusammensetzung
ATE433448T1 (de) Kondensierte heterocyclen und deren verwendungen
DE60216345D1 (de) Gummimischung und deren Verwendung
DK1562918T3 (da) Substituerede benzoxazinoner og anvendelser deraf
DE60221013D1 (de) Mehrschichtiger polymerfilm
DE60216283D1 (de) Thermoplastische elastomerzusammensetzung
DE60323517D1 (de) Hybridisierungsnachweisverfahren und bioassay-vorr
DE60230349D1 (de) Verbesserte Polymerzusammensetzung
DE60305774D1 (de) Schnelle und flexible Bereichsüberprüfung
DE60207362D1 (de) Thermoplastische olefinelastomerzusammensetzung
FI20010711L (fi) Muovimateriaali
DE60202348D1 (de) Thermoplastische Zusammensetzung
EP1687398A4 (en) EXPRESSION CONSTRUCTS THAT DEPEND ON HIV AND USES THEREOF